Initiating highly active antiretroviral therapy and continuity of HIV care: The impact of incarceration and prison release on adherence and HIV treatment outcomes

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 713-719

  Palepu, Anita ^a   Tyndall, Mark W ^a   Chan, Keith ^a   Wood, Evan ^a   Montaner, Julio S G ^a   Hogg, Robert S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PRISON; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PRISONS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 7244236807     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT & Montaner JS. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal 1999; 160:659-665.
2. Revicki DA, Moyle G, Stellbrink HJ & Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. AIDS 1999; 13:851-858.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
4. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM & Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133:21-30.
5. Lucas GM, Cheever LW, Chaisson RE & Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 2001; 27:251-259.
6. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG & Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clinical Infectious Diseases 2002; 35:305-312.
7. Sabin KM, Frey RL, Horsley R & Greby SM. Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998. Journal of Urban Health: Bulletin of the New York Academy of Medicine 2001; 78:241-255.
8. Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, Gao H, Rosenzweig JR, McClernon DR, Pittman G, Hessenthaler SM & Hernandez JE; NZTA4007 Study Team. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clinical Infectious Diseases 2002; 34:511-518.
9. Maruschak LM: Bureau of Justice Statistics Bulletin: HIV in prisons and jails, 1999. Document NCJ 187456, 2001.
10. Hammett TM, Harmon P & Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities. American Journal of Public Health 2002; 92:1789-1794.
11. Rich JD, Holmes L, Salas C, Macalino G, Davis D, Ryczek J & Flanigan T. Successful linkage of medical care and community services for HIV-positive offenders being released from prison. Journal of Urban Health: Bulletin of the New York Academy of Medicine 2001; 78:279-289.
12. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283:381-390.
13. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS & Montaner JSG. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes 2003; 32:522-526.
14. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV & Montaner JS. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
15. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV & Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Annals of Internal Medicine 2003; 139:810-816.
16. Lines R. Action on HIV/AIDS: Too Little, Too Late: A Report Card. 2002; pp. 31-33. Montreal: Canadian HIV/AIDS Legal Network.
17. Stenzel MS, McKenzie M, Mitty JA & Flanigan TP. Enhancing adherence to HAART: a pilot program of modified directly observed therapy. The AIDS Reader 2001; 11:317-328.
18. Altice FL, Mostashari F & Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 28:47-58.
19. Bangsberg DR, Mundy LM & Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. American Journal of Medicine 2001; 110:664-666.
20. Mitty JA, Stone VE, Sands M, Macalino G & Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clinical Infectious Diseases 2002; 34:984-990.
21. Baillargeon J, Borucki MJ, Zepeda S, Jenson HB & Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clinical Infectious Diseases 2000; 31:1476-1481.
22. White MC, Mehrotra A, Menendez E, Estes M, Goldenson J & Tulsky JP. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. International Journal of STD & AIDS 2001; 12:380-385.
23. Kim JY, Rich J, Zierler S, Lourie K, Vigilante K, Normandie L, Snead M, Renzi J, Bury-Maynard D, Loberti P, Richman R & Flanigan TP. Successful community follow-up and reduced recidivism of HIV positive women prisoners. Journal of Correctional Health Care 1997; 4:5-17.
24. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP & Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The MANIF 2000 study group. AIDS 2000; 14:151-155.
25. Lucas GM, Gebo KA, Chaisson RE & Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-774.
26. Lucas GM, Chaisson RE & Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 1999; 131:81-87.
27. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, Howard AA & Schoenbaum EE. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clinical Infectious Diseases 2001; 33:1417-1423.
28. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA & Gazzard BG. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61.
29. Torre D, Tambini R & Speranza F. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. HIV Clinical Trials 2001; 2:113-121.
30. Ghani AC, Henley WE, Donnelly CA, Mayer S & Anderson RM. Comparison of the effectiveness of nonnucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001; 15:1133-1142.
31. Zaccarelli M, Barracchini A, De Longis P, Perno CF, Soldani F, Liuzzi G, Serraino D, Ippolito G & Antinori A. Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care & STDs 2002; 16:67-73.
32. Wood E HR, Heath KV, De La Rosa R, Lee N, Yip B, O'Shaughnessy MV & Montaner JS. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS 2003; 17:2629-2634.
33. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS & Merigan TC; AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 2003; 349:2304-2315.
34. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC & Hirsch MS; AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 2003; 349:2293-2303.
35. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, Richman DD & Wong JK. Prevalence and predictive value of intermittent viremia with combination HIV therapy. Journal of the American Medical Association 2001; 286:171-179.